These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 7980801)

  • 41. Optimal sample size determinations from an industry perspective based on the expected value of information.
    Willan AR
    Clin Trials; 2008; 5(6):587-94. PubMed ID: 19029207
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A Bayesian design and analysis for dose-response using informative prior information.
    Smith MK; Marshall S
    J Biopharm Stat; 2006; 16(5):695-709. PubMed ID: 17037266
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A three-outcome design for randomized comparative phase II clinical trials.
    Hong S; Wang Y
    Stat Med; 2007 Aug; 26(19):3525-34. PubMed ID: 17262879
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Robust Bayesian sample size determination in clinical trials.
    Brutti P; De Santis F; Gubbiotti S
    Stat Med; 2008 Jun; 27(13):2290-306. PubMed ID: 18205170
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A hybrid Bayesian-frequentist approach to evaluate clinical trial designs for tests of superiority and non-inferiority.
    Shao Y; Mukhi V; Goldberg JD
    Stat Med; 2008 Feb; 27(4):504-19. PubMed ID: 17854052
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Bayesian sample size determination under hypothesis tests.
    Zhang X; Cutter G; Belin T
    Contemp Clin Trials; 2011 May; 32(3):393-8. PubMed ID: 21199689
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Comparing methods for calculating confidence intervals for vaccine efficacy.
    Ewell M
    Stat Med; 1996 Nov 15-30; 15(21-22):2379-92. PubMed ID: 8931208
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Optimising the design of phase II oncology trials: the importance of randomisation.
    Ratain MJ; Sargent DJ
    Eur J Cancer; 2009 Jan; 45(2):275-80. PubMed ID: 19059773
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Predictive probability early termination plans for phase II clinical trials.
    Herson J
    Biometrics; 1979 Dec; 35(4):775-83. PubMed ID: 526523
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A randomized two-stage design for phase II clinical trials based on a Bayesian predictive approach.
    Cellamare M; Sambucini V
    Stat Med; 2015 Mar; 34(6):1059-78. PubMed ID: 25545805
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A composite design for transition from a preliminary to a full-scale study.
    Lachin JM; Younes N
    Stat Med; 2007 Nov; 26(27):5014-32. PubMed ID: 17577245
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Sample size determination for phase II clinical trials based on Bayesian decision theory.
    Stallard N
    Biometrics; 1998 Mar; 54(1):279-94. PubMed ID: 9544522
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [How to assess the size of a clinical trial?].
    Paesmans M
    Rev Mal Respir; 1994; 11(6):547-57. PubMed ID: 7831504
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Bayesian evaluation of group sequential clinical trial designs.
    Emerson SS; Kittelson JM; Gillen DL
    Stat Med; 2007 Mar; 26(7):1431-49. PubMed ID: 17066402
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The value of information and optimal clinical trial design.
    Willan AR; Pinto EM
    Stat Med; 2005 Jun; 24(12):1791-806. PubMed ID: 15806619
    [TBL] [Abstract][Full Text] [Related]  

  • 56. New designs for clinical trials.
    Mélot C
    Crit Care Med; 2009 Jan; 37(1 Suppl):S59-64. PubMed ID: 19104226
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Determining optimal sample sizes for multi-stage randomized clinical trials using value of information methods.
    Willan A; Kowgier M
    Clin Trials; 2008; 5(4):289-300. PubMed ID: 18697843
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Sample size reestimation by Bayesian prediction.
    Wang MD
    Biom J; 2007 Jun; 49(3):365-77. PubMed ID: 17623342
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Effect of a misspecification of response rates on type I and type II errors, in a phase II Simon design.
    Baey C; Le Deley MC
    Eur J Cancer; 2011 Jul; 47(11):1647-52. PubMed ID: 21493059
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Approximately optimal designs for phase II clinical studies.
    Stallard N
    J Biopharm Stat; 1998 Jul; 8(3):469-87. PubMed ID: 9741860
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.